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Abstract
Background: Clinical trials with longitudinally measured outcomes are often plagued by missing data due to
patients withdrawing or dropping out from the trial before completing the measurement schedule. The reasons for
dropout are sometimes clearly known and recorded during the trial, but in many instances these reasons are
unknown or unclear. Often such reasons for dropout are non-ignorable. However, the standard methods for
analysing longitudinal outcome data assume that missingness is non-informative and ignore the reasons for
dropout, which could result in a biased comparison between the treatment groups.
Methods: In this article, as a post hoc analysis, we explore the impact of informative dropout due to competing
reasons on the evaluation of treatment effect in the MAGNETIC trial, the largest randomised placebo-controlled
study to date comparing the addition of nebulised magnesium sulphate to standard treatment in acute severe
asthma in children. We jointly model longitudinal outcome and informative dropout process to incorporate the
information regarding the reasons for dropout by treatment group.
Results: The effect of nebulised magnesium sulphate compared with standard treatment is evaluated more
accurately using a joint longitudinal-competing risk model by taking account of such complexities. The
corresponding estimates indicate that the rate of dropout due to good prognosis is about twice as high in the
magnesium group compared with standard treatment.
Conclusions: We emphasise the importance of identifying reasons for dropout and undertaking an appropriate
statistical analysis accounting for such dropout. The joint modelling approach accounting for competing reasons for
dropout is proposed as a general approach for evaluating the sensitivity of conclusions to assumptions regarding
missing data in clinical trials with longitudinal outcomes.
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Background
Although the reasons for all participant dropouts in a
trial may not be known, some might be related to the
unobserved study outcome. Dropout may be caused by
adverse reactions or a lack of effectiveness of the treat-
ment, or it may be affected by the concurrent health sta-
tus of the patient; hence the dropout is often informative
or non-ignorable [1, 2].
Therefore, missing data due to study dropouts are a
potential source of bias when analysing clinical trials,
and it is important to evaluate the effect of informative
dropout on the robustness of the study conclusions.
Trial statisticians often carry out a sensitivity analysis as
a feasible approach for this purpose (e.g., [3, 4]), and this
has also been recommended by the Europe Medicines
Agency Committee for Medicinal Products for Human
Use. A recent review of the handling of missing longitu-
dinal outcome data in clinical trials revealed that 36 %
studies failed to account for reasons for dropout and
carried out just a complete case analysis [5].
In this article, we explore the impact of informative drop-
out due to competing reasons on the evaluation of the ef-
fect of nebulised magnesium sulphate in the MAGNEsium
Trial in Children (MAGNETIC; Current Controlled Trials
identifier ISRCTN81456894). MAGNETIC is the largest
randomised, double-blind, placebo-controlled study to
date comparing the addition of nebulised magnesium
sulphate to standard treatment in acute severe asthma
in children. It was funded by the National Institute
for Health Research (NIHR) Health Technology
Assessment programme. MAGNETIC enrolled chil-
dren from 30 hospitals in the United Kingdom. They
were aged between 2 and 16 years, had severe acute
asthma and did not respond to standard inhaled treat-
ment. The complete eligibility criteria are given in a 2013
article in Health Technology Assessment [6]. Children were
randomly allocated (1:1) to isotonic magnesium sulphate
(MgSO4) or placebo (isotonic saline) on three occasions at
20-minute intervals. The main objective of the trial was to
determine whether the use of nebulised MgSO4, when
given as an adjunct to standard therapy for 60 minutes, re-
sults in a clinical improvement compared with standard
treatment alone. The severity of asthma was assessed
using the validated Yung Asthma Severity Score (ASS).
ASS was recorded at randomisation and then at 20 mi-
nutes (after first nebuliser treatment); 40 minutes (after
second nebuliser treatment); 60 minutes (after third nebu-
liser treatment); and at further follow-up points 120, 180
and 240 minutes post-randomisation. The Yung ASS
ranges from 0 to 9. A low ASS indicates an improved
outcome. In the study, 252 children were randomised
to the magnesium group and 256 to the placebo
group. Further details of the trial, including how sam-
ple size was determined, randomisation, blinding, and
primary and secondary outcomes were published in
2013 in Health Technology Assessment [6] and Lancet
Respiratory Medicine [7]. As with most longitudinal
studies, the MAGNETIC trial also encountered patient
dropout during both the treatment and follow-up phases.
The reasons for dropout were sometimes clearly known
and recorded during the trial; however, in many instances
these reasons were unknown or unclear.
We jointly model longitudinal ASS and dropout
process due to competing risks in the MAGNETIC trial
to incorporate the information regarding the reasons for
dropout in both the magnesium and placebo groups.
Competing risks occur when an event (dropout in this
case) could happen due to several causes, and one cause
excludes the event of interest due to other causes. In the
MAGNETIC trial, competing causes of dropout included
good prognosis, poor prognosis, and unrelated and un-
known reasons. Competing risks are usually analysed
using risk regression models such as cause-specific Cox
proportional hazards or cumulative incidence models
(e.g., [8–10]). More recently, several authors have ex-
tended these models to include longitudinal profiles
through joint longitudinal-competing risks modelling
(e.g., [11–13]). Although such joint analyses are statisti-
cally more efficient for evaluating treatment accounting
for the competing dropout process, to our knowledge
these approaches have been underused in the clinical trials
literature, potentially due to a lack of research that dem-
onstrates the implementation of this approach in practice.
Methods
Dropout definitions
Dropout is defined when sequences of longitudinal mea-
surements in some patients terminate prematurely. In clin-
ical trials, patients who withdrew from the study or were
lost to follow-up were considered as dropouts. The time at
which they withdrew or were lost to follow-up is defined
as the time to dropout. Following the terminology of Dig-
gle and Kenward [14], we define dropout mechanisms as
1. Completely random dropout (CRD): The dropout
and longitudinal processes are independent.
2. Random dropout (RD): The dropout process
depends on the observed longitudinal measurements
(i.e., those preceding dropout).
3. Informative dropout (ID): The dropout process
depends on the unobserved longitudinal
measurements (i.e., those that would have been
observed if the patient had not dropped out).
According to the Rubin [1] terminology for missingness
(rather than “dropout”), CRD, RD and ID mechanisms are
termed missing completely at random, missing at random
and missing not at random, respectively. Motivated by the
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reasons for withdrawals recorded in the MAGNETIC trial,
we can define the dropout process within four possible
categories:
1. Case 1: good prognosis
2. Case 2: poor prognosis
3. Case 3: unknown (or unclear) reasons
4. Case 4: reasons unlikely to be related to the patient’s
concurrent health status
Case 1 is observed if a patient is withdrawn from the trial
due to improving conditions (e.g., discharged from the hos-
pital as the patient was ready to continue treatment at
home). Case 2 is observed if a patient is withdrawn from
the trial due to worsening conditions (e.g., patient needed
more intensive treatment at an intensive care unit or the
occurrence of an adverse event). Both cases 1 and 2 include
dropout reasons that are directly related to the patient’s
concurrent health status; hence both cases depend on the
unobserved longitudinal measurements and should be
classified under the ID mechanism. Any dropout that oc-
curred due to an inconclusive reason (case 3) can be con-
sidered to include a mixture of CRD, RD and ID
mechanisms. Dropout reasons may be identified that are
not likely to be related to a patient’s concurrent health sta-
tus (e.g., protocol deviation, trained assessor not available
to take the measurement). In the MAGNETIC study, po-
tential reasons falling under this fourth category were de-
termined by the chief investigator (CP), with that
assessment undertaken blinded to the treatment allocation.
Standard joint longitudinal and event-time model
In the standard joint model, dropout is treated under ID
mechanism but allows dropout only as a single event-
time process, so the differential reasons for dropout can-
not be considered. The model is defined as shown
below. The longitudinal outcome is assumed to follow a
Gaussian linear model:
Y t ¼ Xβ1 þW 1 tð Þ þ Zt ð1Þ
where W1(t) is a latent zero-mean Gaussian process,
measurement error Zt follows a zero-mean Gaussian
process with variance σ2, that error is independent of the
latent process W1(t), and X allows treatment allocation
and any other covariates. Conditional on latent effects,
W1(t), a single event-time (dropout) process, follows a
semi-parametric proportional hazards model:
λ tjX; W 2 tð Þð Þ ¼ λ0 tð Þexp Xβ2 þW 2 tð Þf g ð2Þ
where W2(t) is a second latent zero-mean Gaussian
process. Within standard formulation, we assume
W1(t) =U0 +U1t in conjunction with a proportionality
assumption W2(t) = γW1(t), where U0 and U1 are
individual random intercept and random slope terms, re-
spectively [15]. The link between W1 and W2 describes
the association between the longitudinal outcome and
dropout process, and γ denotes the strength of this associ-
ation. β1 in model (1) estimates the covariate effects ad-
justed for the dropout process. In model (2), if the
treatment is fitted as a binary covariate X, taking a value 1
if active treatment and 0 if standard, then the correspond-
ing HR eβ2 estimates the risk of dropout in the treatment
group compared with standard (or control) adjusted for
the temporal variation of the longitudinal outcome. The
model parameters can be estimated by maximising the
joint likelihood of the observed data via the expectation-
maximisation (EM) algorithm (see [15] for more details).
Joint longitudinal-competing risks model
The standard joint model with a single mode of dropout
fails to account for the differential effect of treatments on
the reasons for dropout. To account for the informative
dropout due to competing risks, following the approach of
Williamson et al. [13], we assume each competing reason
for dropout follows a semi-parametric, cause-specific pro-
portional hazards sub-model. Dropout due to reasons re-
lated to the lth cause is defined by
λ lð Þ tjX; W 1 tð Þð Þ ¼ λ lð Þ0 tð Þexp Xβ2 lð Þ þ γ lð ÞW 1 tð Þ
n o
; l
¼ 1; 2;…; K
ð3Þ
where W1(t) =U0 +U1t is defined with latent intercept
U0 and slope U1. γ
(l) indicates the level of association be-
tween the longitudinal outcome and lth competing drop-
out process. K is the total number of dropout causes
(e.g., for MAGNETIC, K = 4). If the treatment is fitted as
a binary covariate, taking a value 1 if active treatment
and 0 if standard, then the corresponding HR eβ2
lð Þ
esti-
mates the relative risk of dropout in the treatment group
compared with standard due to reasons related to the lth
cause adjusted for the temporal variation in the longitu-
dinal outcome. The longitudinal outcome is defined by
model (1), and we have fitted the following linear mixed
effects model for the longitudinal ASS:
Y t ¼ β0 þ β1X þ β2tþ U0 þ U1t þ Zt ð4Þ
where U0 ~N(0, σ0
2) and U1 ~N(0, σ1
2) are random
intercept and random slope, respectively, assuming Corr
(U0, U1) = ρ, while the measurement error Zt is defined
as in model (1). X is the treatment covariate taking value
1 if magnesium and 0 if placebo. The predicted ASS for
magnesium (X = 1) at time t is given by β^0 þ β^1 þ β^2t ,
and for placebo (X = 0) it is β^0 þ β^2t. Hence, β1 is the es-
timated difference in ASS in magnesium against placebo
at any time t over follow-up. In the joint competing risks
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model, β1 is adjusted for the association between Yt (lon-
gitudinal ASS) and the competing dropout process.
The model parameters are estimated by maximising
the joint likelihood via the EM algorithm [13]. However,
as K increases, the estimation could become more com-
putationally intensive in a standard computing environ-
ment due to the high number of association parameters.
Further details of the likelihood-based estimation
process are given by Williamson et al. [13]. Bootstrap
sampling with replacement is used to estimate 95 %
CIs [16].
Methods for dealing with complications in MAGNETIC
dropout process
The most efficient approach would be to consider all
possible competing causes of dropout in a competing
risks joint model. However, in the MAGNETIC trial, the
number of patients who dropped out due to poor prog-
nosis (case 2) was low in both treatment groups (see
Table 1), leading to a lack of convergence of the
longitudinal-competing risks model. Therefore, we
propose two separate scenarios. In the first scenario, we
randomly assign case 3 equally between cases 1 and 2
for each treatment group (a more conservative scenario).
The second is the worst-case scenario; here we assume
all unknown reasons for dropout (case 3) were related to
poor prognosis and assign as case 2 for each treatment
group. So, we allow dropout due to unknown reasons
under the ID mechanism. Any case 4 dropout is as-
sumed to have occurred under the CRD mechanism and
thus is independently censored at the time of dropout.
Those who have completed the follow-up schedule
are also independently censored at the final follow-up
of 240 minutes post-randomisation. In the above-
described settings, we explore informative dropout
due to two competing risks (K = 2): good prognosis
and poor prognosis.
Ethical considerations
The MAGNETIC study was approved by the U.K. National
Health Service Multicentre Research Ethics Committee
(MREC 07/H1010/101) and by the U.K. National Health
Service Medicines for Children Research Network. Written
informed consent was obtained from a parent or guardian
of each child who was enrolled in the study.
Results and discussion
The MAGNETIC trial data includes 248 children (49 %)
in the magnesium group and 254 children (51 %) in the
placebo group. The Consolidated Standards of Reporting
Trials (CONSORT) flow diagram and checklist are pre-
sented for this analysis (see Additional files 1 and 2).
Table 1 presents the summary of the dropout process in
MAGNETIC. A higher overall dropout rate is observed
in the magnesium group than in the placebo arm, with
some suggestion that the reasons for dropout differ be-
tween groups. Figure 1 shows the mean longitudinal ASS
profiles for those who have completed the follow-up
schedule and for those who have dropped out at each as-
sessment point, together with the overall dropout profile.
Dropouts in the magnesium group occurred with lower
ASS due to patients improving and being discharged be-
fore the end of follow-up, whereas early dropouts in the
placebo group occurred with higher ASS as a result of
patients worsening and needing more intense treatment.
Although the graphical summaries of ASS dropout trajec-
tories indicated that most children were clinically well and
ready to be discharged at the time of withdrawal from the
trial in the magnesium group [6], this claim is yet to be
justified on the basis of a formal statistical analysis.
Standard analyses ignoring competing dropout reasons
The results from two standard analyses are shown in
Table 2. The complete case analysis is the most common
method and is usually undertaken before the sensitivity
analyses. The complete case analysis excludes patients
who dropped out of the study, assuming that patients
who dropped out are the same as those who completed
the trial; in other words, it assumes a CRD mechanism for
all dropouts. To illustrate the method, we have fitted the
linear mixed effect model (4) for the longitudinal ASS for
those who had completed the follow-up schedule at all t at
0, 20, 40, 60, 120, 180 and 240 minutes (n = 402 patients)
(Table 1). The model has estimated a non-significant
Table 1 Summary of dropout reasons by treatment at the final follow-up
Status Magnesium, n (%) Placebo, n (%) Total, n (%)
Baseline ASS assessment completed 248 (49.4) 254 (50.6) 502
Completed follow-up 185 (74.6) 217 (85.4) 402 (80.1)
Overall dropout 63 (25.4) 37 (14.6) 100 (19.9)
Case 1: Due to good prognosis 10 (15.9) 5 (13.5) 15 (15.0)
Case 2: Due to poor prognosis 1 (1.6) 3 (8.1) 4 (4.0)
Case 3: Due to unknown or unclear reasons 11 (17.4) 9 (24.3) 20 (20.0)
Case 4: Unlikely to be related to the patient’s concurrent health status 41 (65.1) 20 (54.1) 61 (61.0)
ASS Asthma Severity Score
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treatment effect ( β^1 ¼ −0.086, 95 % CI −0.297 to 0.125),
implying that MgSO4 shows no improvement of ASS
against placebo over time. The primary analysis of the
MAGNETIC trial was an analysis of covariance to test the
hypothesis of no difference between the two treatment
arms at t = 60 minutes, and a difference of −0.25 points
(95 % CI −0.48 to −0.02) was noted, which lies above
the minimum clinically important difference of 0.5 points
[6, 7]. The current model takes the variation of ASS over
the entire follow-up and estimates a difference of −0.086.
However, the assumed CRD mechanism is evidently in-
correct for the MAGNETIC trial, as some of the reasons
for dropout were clearly related to the patient’s concurrent
health status, and some were unknown (Table 1).
The standard joint longitudinal ASS and dropout
model assumes all dropouts occur under the ID
mechanism (as a single event-time process) and is fitted by
Y t ¼ β0 þ β1X þ β2tþW 1 tð Þ þ Zt
λ tjX; W 1 tð Þð Þ ¼ λ0 tð Þexp β2X þ γW 1 tð Þ
 
where X is the treatment covariate taking value 1 if mag-
nesium and 0 if placebo; t can take values in 0, 20, 40,
60, 120, 180 and 240 minutes before dropout; and
W1(t) =U0 +U1t. This analysis includes the entire sample
of 502 patients, and the model estimates a statistically
significant improvement in ASS for MgSO4 over placebo
(β1 = −0.193, 95 % CI −0.381 to −0.010). The estimated as-
sociation parameter γ = −0.211 (95 % CI −0.442 to −0.017)
implies that dropout is associated with lower ASS, and the
corresponding HR = 1.832 (95 % CI 1.238 to 2.772) indi-
cates that the risk of dropout is significantly higher in the
magnesium group. As low ASS indicates better asthma
control, the estimated γ and HR parameters indicate that
dropouts in the magnesium group had significantly low
ASSs and that MgSO4 significantly reduces ASS. However,
the standard joint analysis has ignored the differential
effects of magnesium and placebo on reasons for
dropout, and also that some reasons for dropout are
unknown. Therefore, the validity of the above-mentioned
claim is questionable.
Analysis of informative dropout due to competing
reasons
Figure 2 shows mean longitudinal ASS dropout profiles
for the four cases, together with the mean profiles for
those who have completed the follow-up schedule and
0 60 120 180 240
Magnesium
Time (minutes)
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5
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9
A
S
S
Completed (185, 74.6%)
Overall dropout (63, 25.4%)
Dropout at T180
Dropout at T120
Dropout at T60
Dropout at T40
Dropout at T20
Dropout at T0
0 60 120 180 240
1
2
3
4
5
6
7
8
9
Placebo
Time (minutes)
A
S
S
Completed (217, 85.4%)
Overall dropout (37, 14.6%)
Dropout at T180
Dropout at T120
Dropout at T60
Dropout at T40
Dropout at T20
Dropout at T0
Fig. 1 Longitudinal mean Asthma Severity Score (ASS) profiles for groups according to whether they completed follow-up or dropped out
Table 2 Estimates (95 % CI) from the complete case and standard joint modellinga analyses
Model Longitudinal outcome Dropout
β1 (95 % CI) HR (95 % CI) γ (95 % CI)
Complete case analysis (n = 402) −0.086 (−0.297 to 0.125) – –
Standard joint model (n = 502, overall dropouts = 100) −0.193 (−0.381 to −0.010) 1.869 (1.238 to 2.772) −0.211 (−0.442 to −0.017)
a95 % bias-corrected percentile CIs are obtained from 1000 bootstrap resamples
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the overall dropout profile. The mean profile of the three
patients who dropped out due to poor prognosis (case 2)
from the placebo group shows the highest ASS. The mean
dropout profiles from case 4 remain similar to the profiles
of those completing follow-up in both treatment groups.
Therefore, the CRD mechanism seems a reasonable as-
sumption for the case 4 group. However, mean dropout
profiles for case 3 are clearly positioned on opposite sides
from those completing for the magnesium and placebo
groups; for the magnesium group, it is below (lower ASS,
better prognosis) the profile for those who completed,
whereas for the placebo group, it is above (higher
ASS, worse prognosis). Case 3 should be considered
under the ID mechanism in any analysis. Ignoring
this situation could induce bias when estimating the
treatment effect.
As discussed in the Methods section, we have re-defined
cases 1 and 2 under the two scenarios. For scenario 1, of
0 60 120 180 240
1
Magnesium
Time (minutes)
A
S
S
Completed (185, 74.6%)
Overall dropout (63, 25.4%)
Case 1 (10, 4.0%)
Case 2 (1, 0.4%)
Case 3 (11, 4.4%)
Case 4 (41, 16.5%)
0 60 120 180 240
1
2
3
4
5
6
7
8
9
2
3
4
5
6
7
8
9
Placebo
Time (minutes)
A
S
S
Completed (217, 85.4%)
Overall dropout (37, 14.6%)
Case 1 (5, 2.0%)
Case 2 (3, 1.2%)
Case 3 (9, 3.5%)
Case 4 (20, 7.9%)
Fig. 2 Longitudinal mean Asthma Severity Score (ASS) profiles for competing dropout processes, together with the mean ASS profile for those
who completed
0 60 120 180 240
1
Magnesium
Time (minutes)
A
S
S
Censored (226, 91.1%)
Case 1 (16, 6.5%)
Case 2 (6, 2.4%)
0 60 120 180 240
1
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4
5
6
7
8
9
Placebo
Time (minutes)
A
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S
Censored (237, 93.3%)
Case 1 (9, 3.5%)
Case 2 (8, 3.1)
Fig. 3 Scenario 1 (conservative): mean longitudinal Asthma Severity Score (ASS) profiles
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the 11 patients in case 3 in the magnesium group, 6 are
assigned as case 1 and 5 as case 2 randomly, and of the 9
patients in placebo group, 4 are assigned as case 1 and 5 as
case 2. Figures 3 and 4 show the corresponding mean ASS
profiles for re-defined cases 1 and 2 under scenarios 1 and
2, respectively. For each scenario, we fit the joint ASS and
competing risks model as follows:
Y t ¼ β0 þ β1X þ β2tþW 1 tð Þ þ Zt
λ 1ð Þ tjX; W 1 tð Þð Þ ¼ λ 1ð Þ0 tð Þexp β2 1ð ÞX þ γ 1ð ÞW 1 tð Þ
n o
λ 2ð Þ tjX; W 1 tð Þð Þ ¼ λ 2ð Þ0 tð Þexp β2 2ð ÞX þ γ 2ð ÞW 1 tð Þ
n o
where X, t and W1(t) are defined as above. The second
and third components of the model are related to l = 1
and 2 in model (3) and allow reasons for dropout due to
good and poor prognosis, respectively. These analyses
include the entire sample of 502 patients, and the corre-
sponding estimates are given in Table 3. Scenario 1 has
been performed for a number of different random
allocations to include ten patients each in cases 1 and 2,
and all such allocations resulted in fairly similar
estimates. The model estimates corresponding to the
above-mentioned random allocation are presented in
Table 3, and this model included 25 patients in case 1
and 14 in case 2. In scenario 2, case 1 includes 15 pa-
tients and case 2 includes 24 patients.
Once the reasons for dropout were taken into ac-
count, the estimated improvement with respect to
ASS for MgSO4 over placebo by the standard joint
model (β1 = −0.193) was reduced by about 15 % in
both scenarios (−0.163 and −0.165, respectively) and
both estimates of β1 became non-significant; however,
the change in absolute terms (0.03 and 0.028, respect-
ively) was small and the estimated treatment effects
(−0.163 and −0.165, respectively) remained above the
minimum clinically important difference of 0.5 points
[6, 7]. We expect this reduction in β1 estimates, given
the differential ASS profiles between magnesium and
placebo for the two competing dropout reasons, as
shown in Figs. 3 and 4, which is not taken into ac-
count in the standard joint model.
For scenario 1, the estimated association parameter
γ(1) = −0.768 (95 % CI −1.340 to −0.299) implies that
dropout due to good prognosis is strongly associated with
0 60 120 180 240
1
Magnesium
Time (minutes)
A
S
S
Completed (226, 91.1%)
Case 1 (10, 4.0%)
Case 2 (12, 4.8%)
0 60 120 180 240
1
2
3
4
5
6
7
8
9
2
3
4
5
6
7
8
9
Placebo
Time (minutes)
A
S
S
Completed (237, 93.3%)
Case 1 (5, 2.0%)
Case 2 (12, 4.7%)
Fig. 4 Scenario 2 (worst): mean longitudinal Asthma Severity Score (ASS) profiles
Table 3 Estimates (95 % CIa) from the joint longitudinal-competing risks model for scenario 1 (conservative) and scenario 2 (worst)
Scenario Longitudinal outcome Dropout due to good prognosis Dropout due to poor prognosis
β1 (95 % CI) HR(1) (95 % CI) γ(1) (95 % CI) HR(2) (95 % CI) γ(2) (95 % CI)
1 (n = 502 case 1: 25
case 2: 14)
−0.165 (−0.336 to 0.011) 1.915 (0.820 to 3.507) −0.768 (−1.340 to −0.299) 0.801 (0.122 to 1.872) 0.200 (−0.436 to 0.715)
2 (n = 502 case 1: 15
case 2: 24)
−0.163 (−0.363 to 0.010) 2.125 (0.845 to 3.904) −1.389 (−2.021 to −0.938) 1.069 (0.350 to 2.148) 0.159 (−0.361 to 0.588)
a95 % bias-corrected percentile CIs are obtained from 1000 bootstrap resamples
Kolamunnage-Dona et al. Trials  (2016) 17:222 Page 7 of 9
low ASS; however, the HR, eβ2 1ð Þ = 1.915 (95 % CI 0.820 to
3.507) implies that such dropout is not significantly higher
in the magnesium group than that in the placebo group.
γ(2) = 0.200 (95 % CI −0.436 to 0.715) and the HR,
eβ2
2ð Þ = 0.801 (95 % CI 0.122 to 1.872), imply that dropout
due to poor prognosis is not evident in the magnesium
group. The estimates from the worst case scenario
(scenario 2) are also indicated as the same; however,
the association parameter γ(1) = −1.389 (95 % CI −2.021
to −0.938) implies a much stronger association between
ASS and risk of dropout due to good prognosis. In both
scenarios, the corresponding HR estimates (1.915 in sce-
nario 1 and 2.125 in scenario 2) indicate that the rate of
dropout due to good prognosis is about twice as high in
the magnesium group as in the placebo group. Further, for
both scenarios, positive estimates of γ(2) imply that pa-
tients with higher ASS have increased risk of dropout due
to poor prognosis, and the negative estimates of γ(1) imply
that patients with low ASS have increased risk of dropout
due to good prognosis. Therefore, the above analysis sup-
ports the assertion that most children in the magnesium
group were clinically well at the time of withdrawal from
the trial and that the estimated association parameters
and corresponding HRs reveal the true impact of MgSO4
on ASS.
Conclusions
Clinical trialists often perform sensitivity analyses to study
the robustness of the estimated treatment effect to missing
data. However, most sensitivity analyses are based on sim-
ple imputation methods (such as last observation carried
forward or mean substitution [5]) and usually assume a
CRD mechanism; hence they may fail when the reason for
dropout is unknown or unclear and informative. Accord-
ing to a recent review [5], MAGNETIC is the first clinical
trial that in which researchers have reported fitting the
standard joint model in a sensitivity analysis to account for
informative dropout [6]. Such statistically more effi-
cient methodologies are currently underused in
clinical trials analyses due to a lack of awareness
resulting from limited examples of their application in
practice. In this article, we have reported the dropout
process in the MAGNETIC trial in more detail and
demonstrated the use of a more efficient statistical
methodology within the joint modelling framework to
deal with the complex dropout process in the trial.
Although the proposed methods were based on
MAGNETIC trial data, they are generalisable across
other longitudinal studies. We have programmed in R
language to estimate the model parameters; however,
a variety of software with alternative estimation pro-
cedures are available for this class of models, includ-
ing the Bayesian approaches (e.g., SAS [SAS Institute,
Cary, NC, USA], C, WinBUGS). The R code is avail-
able from the corresponding author on request.
We emphasise the importance of identifying reasons
for dropout and undertaking statistically efficient ana-
lysis accounting for such dropout. The joint modelling
approaches accounting for competing reasons for drop-
out is proposed as a general approach for evaluating the
sensitivity of conclusions to assumptions regarding miss-
ing data in clinical trials with longitudinal outcomes.
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